Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

UCB

Status and phase: Completed; Phase 2

Conditions: Dyskinesia, Medication-induced

Treatments: Drug: Levetiracetam

Study type: Interventional

Funder types: Industry

Identifiers

NCT00175955

N01142

EudraCT Number 2004-001302-27

Details and patient eligibility

About

An 8-week study to examine safety and efficacy of levetiracetam in patients with neuroleptic-induced tardive dyskinesia

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects between ages 18 and 80 years
• Subjects must have a diagnosis of stable axis I psychiatric disorder at least 6 months prior to screening
• Subjects must have a stable neuroleptic-induced tardive dyskinesia at least 1 month prior to screening and meet tardive dyskinesia severity criteria
• Subjects must have used antipsychotics for at least 6 cumulative months, and, be on a stable dose for 1 month prior to screening

Exclusion criteria

• Presence of any axis II condition within 6 months prior to screening
• Huntington´s disease, idiopathic dystonia, Wilson´s disease, Sydenham´s chorea, thyroid dysfunction, spontaneous dyskinesia
• Start of drugs-other than neuroleptics- that can cause dyskinesia
• Presence of additional major disease such as cardiac, renal or hepatic dysfunction or terminal illness